Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolTSE:VRX
CUSIPN/A
Phone+1-514-7446792
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins58.58%
Return on Equity112.73%
Return on Assets12.76%
Miscellaneous
EmployeesN/A
Outstanding Shares349,299,000
Valeant Pharmaceuticals Intl (TSE:VRX) Frequently Asked Questions
What is Valeant Pharmaceuticals Intl's stock symbol?
Valeant Pharmaceuticals Intl trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VRX."
How were Valeant Pharmaceuticals Intl's earnings last quarter?
Valeant Pharmaceuticals Intl Inc (TSE:VRX) issued its quarterly earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported $1.12 EPS for the quarter, topping the Zacks' consensus estimate of $0.85 by $0.27. The specialty pharmaceutical company had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.54 billion. Valeant Pharmaceuticals Intl had a return on equity of 112.73% and a net margin of 58.58%. View Valeant Pharmaceuticals Intl's Earnings History.
When is Valeant Pharmaceuticals Intl's next earnings date?
What price target have analysts set for VRX?
3 brokerages have issued 1 year price objectives for Valeant Pharmaceuticals Intl's stock. Their predictions range from C$23.00 to C$25.50. On average, they anticipate Valeant Pharmaceuticals Intl's share price to reach C$24.25 in the next twelve months. View Analyst Ratings for Valeant Pharmaceuticals Intl.
Who are some of Valeant Pharmaceuticals Intl's key competitors?
Some companies that are related to Valeant Pharmaceuticals Intl include MERCK KGAA/S (MKKGY), Merck KGaA (MRK), Canopy Growth (WEED), Aurora Cannabis (ACB), STADA Arzneimittel (SAZ), Hikma Pharmaceuticals (HKMPY), Hikma Pharmaceuticals (HIK), Aphria (APH), MedReleaf (LEAF), Knight Therapeutics (KHTRF), Hydropothecary (THCX), OrganiGram (OGI), Supreme Cannabis (FIRE), Weed (BUDZ) and OrganiGram (OGRMF).
Who are Valeant Pharmaceuticals Intl's key executives?
Valeant Pharmaceuticals Intl's management team includes the folowing people:
- Mr. Joseph C. Papa, CEO & Chairman (Age 63)
- Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
- Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
- Mr. J. Michael Pearson, Former Chief Exec. Officer (Age 59)
- Mr. Osama A. Eldessouky, Sr. VP, Controller & Chief Accounting Officer (Age 46)
Has Valeant Pharmaceuticals Intl been receiving favorable news coverage?
News headlines about VRX stock have trended somewhat positive this week, according to Accern. The research group ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Valeant Pharmaceuticals Intl earned a news impact score of 0.18 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 45.75 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Valeant Pharmaceuticals Intl?
Shares of VRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Valeant Pharmaceuticals Intl's stock price today?
One share of VRX stock can currently be purchased for approximately C$32.86.
How big of a company is Valeant Pharmaceuticals Intl?
Valeant Pharmaceuticals Intl has a market capitalization of C$7.69 billion.
How can I contact Valeant Pharmaceuticals Intl?
Valeant Pharmaceuticals Intl's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-7446792.
MarketBeat Community Rating for Valeant Pharmaceuticals Intl (VRX)
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe VRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
